Abiomed Paves Bridge-To-Recovery Market On Road To Destination Therapy
This article was originally published in The Gray Sheet
Executive Summary
Abiomed is refocusing its ventricular-assist device (VAD) sales efforts on open-heart surgery instead of transplant centers to climb out of an unprofitable quarter and sequential loss of revenue